Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test


HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy

Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), and that it is now available for sale within Canada.

HaluGen’s psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one’s psychedelic assisted therapy experience. By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic assisted therapy patient care and reduce side effects and risk. The first of its kind, the proprietary test kit and platform are also expected to be available for purchase in US market within the coming months. The Company is currently pursuing various strategic partnerships with the goal of building brand awareness.

For more information on pricing and ordering, please visit HaluGen’s website at www.HaluGen.com.

HaluGen’s genetic-based testing platform was developed and tested in partnership with Lobo Genetics Inc. (“Lobo”), a Toronto-based healthcare technology company that has successfully commercialized a THC and CBD Genetic Test. Based on a Product Supply and Testing Services Agreement between Lobo and HaluGen, Lobo completed the requirements for the commercialization of the Psychedelic Pre-Screening Genetic Test, including the completion of the Assay Development and Technology Platform; the creation of operating procedures and the deployment and successful testing of the technology platform.

The Psychedelics Genetic Test leverages Polymerase Chain Reaction (PCR) technology, which is a well-established method for genotyping and analyzing DNA. Customers receive a swab kit that is shipped directly to their home which they can then register on HaluGen’s secure online portal. After a non-invasive cheek swab sample is taken, the kit is returned to be processed at HaluGen’s Toronto-based testing facility. A personalized genetic profile with five individualized sensitivity and risk reports is sent directly to the customer and they are also given access to pre-screening mental health surveys and relevant peer-reviewed scientific studies.

Genetics can play an important role in how an individual responds to psychedelic-assisted psychotherapy. For example, the HTR2A gene mutation, carried by ~20% of the population, can impact how a person responds to serotonin, which is the primarily mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT. Another gene, CYP2B6, can influence the metabolism of ketamine for the 10-20% of people that carry a specific CYP2B6 gene…

Read More: Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Leave a reply